Entresto
Valsts: Eiropas Savienība
Valoda: angļu
Klimata pārmaiņas: EMA (European Medicines Agency)
Lietošanas instrukcija
(PIL)
08-12-2023
Produkta apraksts
(SPC)
08-12-2023
Publiskā novērtējuma ziņojums
(PAR)
22-06-2023
Aktīvā sastāvdaļa:
sacubitril, valsartan
Pieejams no:
Novartis Europharm Limited
ATĶ kods:
C09DX04
SNN (starptautisko nepatentēto nosaukumu):
sacubitril, valsartan
Ārstniecības grupa:
Angiotensin II antagonists, other combinations, Agents acting on the renin-angiotensin system
Ārstniecības joma:
Heart Failure
Ārstēšanas norādes:
Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Produktu pārskats:
Revision: 18
Autorizācija statuss:
Authorised
Autorizācija datums:
2015-11-19
Lietošanas instrukcija
76
B. PACKAGE LEAFLET
77
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ENTRESTO 24 MG/26 MG FILM-COATED TABLETS
ENTRESTO 49 MG/51 MG FILM-COATED TABLETS
ENTRESTO 97 MG/103 MG FILM-COATED TABLETS
sacubitril/valsartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Entresto is and what it is used for
2.
What you need to know before you take Entresto
3.
How to take Entresto
4.
Possible side effects
5.
How to store Entresto
6.
Contents of the pack and other information
1.
WHAT ENTRESTO IS AND WHAT IT IS USED FOR
Entresto is a heart medicine containing an angiotensin receptor
neprilysin inhibitor. It delivers two
active substances, sacubitril and valsartan.
Entresto is used to treat a type of long-term heart failure in adults,
children and adolescents (one year
and older).
This type of heart failure occurs when the heart is weak and cannot
pump enough blood to the lungs
and the rest of the body. The most common symptoms of heart failure
are breathlessness, fatigue,
tiredness and ankle swelling.
78
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
ENTRESTO
DO NOT TAKE ENTRESTO
•
if you are allergic to sacubitril, valsartan or any of the other
ingredients of this medicine (listed
in section 6).
•
if you are taking another type of medicine called an angiotensin
converting enzyme (ACE)
inhibitor (for example enalapril, lisinopril or ramipril), which is
used to treat high blood
pressure or heart failure. If you have been taking an ACE inhibitor,
wait for 36 hours after
taking the last dose before you sta
Izlasiet visu dokumentu
Produkta apraksts
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Entresto 24 mg/26 mg film-coated tablets
Entresto 49 mg/51 mg film-coated tablets
Entresto 97 mg/103 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Entresto 24 mg/26 mg film-coated tablets
Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg
valsartan (as sacubitril valsartan
sodium salt complex).
Entresto 49 mg/51 mg film-coated tablets
Each film-coated tablet contains 48.6 mg sacubitril and 51.4 mg
valsartan (as sacubitril valsartan
sodium salt complex).
Entresto 97 mg/103 mg film-coated tablets
Each film-coated tablet contains 97.2 mg sacubitril and 102.8 mg
valsartan (as sacubitril valsartan
sodium salt complex).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Entresto 24 mg/26 mg film-coated tablets
Violet white ovaloid biconvex film-coated tablet with bevelled edges,
unscored, debossed with “NVR”
on one side and “LZ” on the other side. Approximate tablet
dimensions 13.1 mm x 5.2 mm.
Entresto 49 mg/51 mg film-coated tablets
Pale yellow ovaloid biconvex film-coated tablet with bevelled edges,
unscored, debossed with “NVR”
on one side and “L1” on the other side. Approximate tablet
dimensions 13.1 mm x 5.2 mm.
Entresto 97 mg/103 mg film-coated tablets
Light pink ovaloid biconvex film-coated tablet with bevelled edges,
unscored, debossed with “NVR”
on one side and “L11” on the other side. Approximate tablet
dimensions 15.1 mm x 6.0 mm.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Adult heart failure
Entresto is indicated in adult patients for treatment of symptomatic
chronic heart failure with reduced
ejection fraction (see section 5.1).
Paediatric heart failure
Entresto is indicated in children and adolescents aged one year or
older for treatment of symptomatic
chronic heart failure with left ventricular systolic dysfunction (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_General considerations
Izlasiet visu dokumentu
